読み込み中
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$23.12
−$0.07 · -0.30%
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
前日終値
$23.12
−$0.07 · -0.30%
日中の時刻はETです。市場データは遅延する場合があります。
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
日中レンジ
現在 $23.12
52週レンジ
現在 $23.12
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
80
割安
センチメント
61
強気
リスク
58
やや高いリスク
モメンタム
50
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
日中レンジ
現在 $23.12
52週レンジ
現在 $23.12
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI96.59万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF49万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC11.85万0.01%13.17億 USD0.60%$183+0.11%
U.S. Micro Cap Portfolio ETFDFMC6.07万0.00%75.58億 USD0.43%$57.813+0.20%
Dimensional - US Small Cap ETFDFAS4.13万0.00%338.69億 USD0.31%$78.35+0.32%
Dimensional - US Sustainability Core 1 ETFDFSU2.34万0.00%23.92億 USD0.15%$48.11+0.48%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.69万0.00%455.91億 USD0.17%$84.44+0.44%
Dimensional - US Core Equity 2 ETFDFAC1.34万0.00%885.96億 USD0.21%$45.33+0.49%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCDimensional - US Small Cap ETFDFASDimensional - US Sustainability Core 1 ETFDFSUU.S. Core Equity 1 Portfolio ETF Class SharesDCORDimensional - US Core Equity 2 ETFDFACAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
